The Global. The Valencian Community has committed to promoting biosimilar medicines. Currently, according to data from the Regional Health Department, these drugs have a market penetration of 16,5 percent, counted as a percentage of the total amount of biological drugs consumed. The Valencian commitment intends to exceed this figure by almost 10 points during 2016, with the ultimate goal of reaching 25 percent penetration. 'Currently there are five biosimilars available for use in the hospital environment (erythropoietin, follitropin, somatropin, filgrastim, infliximab) and another for outpatient use (insulin), recently marketed', they say from the counseling in reference to the drugs that They will be promoted from the regional health portfolio.